Item 8.01. Other Events.

On December 8, 2022, Eiger BioPharmaceuticals, Inc. issued a press release titled "Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.                                    Description

99.1          Press release, dated December 8, 2022, titled "Eiger Announces Both
            Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in
            Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against
            Placebo in Composite Primary Endpoint."

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses